Preclinical assessment of 90Y-labeled monoclonal antibody CO17-1A, a potential agent for radioimmunotherapy of colorectal carcinoma.

Abstract

Monoclonal antibody CO17-1A was radiolabeled with 90Y using the cyclic DTPA anhydride technique and administered intravenously to athymic nude mice bearing SW 948 human colorectal carcinomas. The tumor specificity of 90Y-CO17-1A was improved by coadministration of 100 micrograms of the unlabeled antibody per animal and by purification using HPLC instead of column gel filtration chromatography. Absorbed radiation dose estimates for 90Y-CO17-1A were calculated. The radiation dose to the bone marrow will limit the amount of 90Y-CO17-1A that can be administered for cancer therapy.

• Authors: L C Washburn, Y C Lee, T T Sun, B Byrd, J E Crook, M G Stabin, Z Steplewski
• Journal: International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology (Int J Rad Appl Instrum B) Vol. 15 Issue 6 Pg. 707-11 ( 1988) ISSN: 0883-2897 [Print] England
• PMID: 3251904 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibodies, Monoclonal
• Yttrium Radioisotopes

Topics

• Animals
• Antibodies, Monoclonal (therapeutic use)
• Colorectal Neoplasms (radiotherapy)
• Female
• Humans
• Mice
• Mice, Nude
• Neoplasm Transplantation
• Tissue Distribution
• Transplantation, Heterologous
• Yttrium Radioisotopes (therapeutic use)